日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶 1 (IDH1) 和 IDH2 突变型胆管癌:来自美国国家癌症研究所 10129 II 期试验的安全性和抗肿瘤活性

Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das, Biswajit; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

针对实体瘤和淋巴瘤患者的茚并异喹啉类化合物LMP776和LMP744的I期研究

O'Sullivan Coyne, Geraldine; Kummar, Shivaani; Rubinstein, Larry V; Wilsker, Deborah; Moore, Nancy; Hogu, Murielle; Piekarz, Richard; Covey, Joe; Beumer, Jan H; Ferry-Galow, Katherine V; Villaruz, Liza C; Hollingshead, Melinda G; Holleran, Julianne L; Deppas, Joshua J; Pommier, Yves; Ko, Brian; Johnson, Barry C; Parchhment, Ralph E; Ivy, Percy; Doroshow, James H; Chen, Alice P

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

NCI10066:一项奥拉帕尼联合雷莫芦单抗治疗既往接受过治疗的转移性胃癌和胃食管交界处腺癌的1/2期研究

Cecchini, Michael; Cleary, James M; Shyr, Yu; Chao, Joseph; Uboha, Nataliya; Cho, May; Shields, Anthony; Pant, Shubham; Goff, Laura; Spencer, Kristen; Kim, Edward; Stein, Stacey; Kortmansky, Jeremy S; Canosa, Sandra; Sklar, Jeffrey; Swisher, Elizabeth M; Radke, Marc; Ivy, Percy; Boerner, Scott; Durecki, Diane E; Hsu, Chih-Yuan; LoRusso, Patricia; Lacy, Jill

Expanding access to early phase trials: the CATCH-UP.2020 experience

扩大早期临床试验的参与机会:CATCH-UP.2020 的经验

Baranda, Joaquina C; Diaz, Francisco J; Rubinstein, Larry; Shields, Anthony F; Dayyani, Farshid; Mehta, Amitkumar; Mehnert, Janice M; Trent, Jonathan; Mabaera, Rodwell; Mooney, Margaret; Moscow, Jeffrey A; Doroshow, James; Waters, Brittany; Ivy, Percy; Gore, Steven D; Thomas, Alexandra

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

一项针对晚期实体恶性肿瘤患者的 I 期研究,评估了口服 VEGFR 抑制剂 cediranib 与口服 MEK 抑制剂 selumetinib 联合用药的疗效。

Hubbard, Joleen M; Yin, Jun; Schenk, Erin L; Qin, Rui; Reid, Joel M; Strand, Carrie; Fiskum, Jack; Menefee, Michael; Lin, Grace; Doyle, L Austin; Ivy, Percy; Erlichman, Charles; Adjei, Alex; Haluska, Paul; Costello, Brian A

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors

HSP90抑制剂onalespib联合泛CDK抑制剂AT7519治疗晚期实体瘤患者的I期研究

Do, Khanh T; O'Sullivan Coyne, Geraldine; Hays, John L; Supko, Jeffrey G; Liu, Stephen V; Beebe, Kristin; Neckers, Len; Trepel, Jane B; Lee, Min-Jung; Smyth, Tomoko; Gannon, Courtney; Hedglin, Jennifer; Muzikansky, Alona; Campos, Susana; Lyons, John; Ivy, Percy; Doroshow, James H; Chen, Alice P; Shapiro, Geoffrey I

Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Brachytherapy in Puerto Rico After Hurricane Maria

飓风玛丽亚过后,利用美国国家癌症研究所项目合作在波多黎各开展子宫颈癌近距离放射治疗

Kunos, Charles A; Ivy, Percy

LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma

采用液相色谱-串联质谱法定量测定人血浆中ATR激酶抑制剂VX-970的含量

Kiesel, Brian F; Scemama, Jonas; Parise, Robert A; Villaruz, Liza; Iffland, Andre; Doyle, Austin; Ivy, Percy; Chu, Edward; Bakkenist, Christopher J; Beumer, Jan H

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials

利用硼替佐米剂量探索临床试验数据进行剂量优化的案例分析

Lee, Shing M; Backenroth, Daniel; Cheung, Ying Kuen Ken; Hershman, Dawn L; Vulih, Diana; Anderson, Barry; Ivy, Percy; Minasian, Lori

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors

一项针对难治性实体瘤的γ-分泌酶抑制剂RO4929097联合卡培他滨的多中心I期研究

LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy; Tevaarwerk, Amye; Leverence, Rachael; Kolesar, Jill; Siu, Lillian; Lubner, Sam J; Mulkerin, Daniel L; Schelman, William R; Deming, Dustin A; Holen, Kyle D; Carmichael, Lakeesha; Eickhoff, Jens; Liu, Glenn